 |
3 Companies | 2 Products |
|
|
2 Products | |
6 Diseases | |
1 Trial |  |
108 News |  |
- | Journal: ICOS limits memory-like properties and function of exhausted PD-1 + CD8 T cells. (Pubmed Central) - Sep 30, 2024
In a mouse model of hepatocellular carcinoma, ICOS inhibition improved cytokine production by tumor-specific PD-1 + CD8 T cells and delayed tumor growth. Overall, we show that ICOS limits CD8 T cell responses during chronic antigen exposure.
- BRCA mutations may induce immune-resistance in breast cancer patients treated with IO-only approach: a retrospective analysis. (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_344;
Conclusions In our small retrospective cohort, the presence of a pathogenic mutation in BRCA1/2 genes resulted in reduced benefit to IO-alone approach. If confirmed in a wider and prospective cohort, these results could guide the decision on first-line treatment of BRCAm TNBC.
- imatinib / Generic mfg.
T cell Inducible Costimulator (ICOS) blockade increases the efficacy of imatinib in Gastrointestinal Stromal Tumor (GIST) (Ballroom A) - Jan 3, 2023 - Abstract #SSO2023SSO_139;
ICOS is a new potential target for immunotherapy against human GIST. Learning Objectives: describe the relationship between ICOS expression / blockade and anti-inflammatory IL-10 producing regulatory T cells describe the anti-tumoral effects of ICOS blockade alone and in combination with imatinib in murine GIST list the cell types expressing ICOS and ICOSL
- | Journal, PD(L)-1 Biomarker, IO biomarker: The immune landscape of undifferentiated pleomorphic sarcoma. (Pubmed Central) - Nov 1, 2022
We identified three immunologically distinct clusters of UPS Associated with OS and DFS. Our data support further investigations of combination anti-PD-1/PD-L1 and adenosine pathway inhibitors in UPS.
- ICOS and ICOSL are novel biomarkers for multiple myeloma (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_1319;
Conclusion Results suggests that ICOS and ICOSL may be novel markers and therapy targets for MM. Finally, the fact that ICOS and ICOSL are expressed not only on myeloma cells, but also on several cell types of the myeloma niche suggests that these molecules may be targeted in MM therapy.
- | Journal, IO biomarker: Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma. (Pubmed Central) - Apr 9, 2022
This work comprehensively analyzed the role and mechanism of TMEMs in LUAD and revealed the characteristics of histone methylation modification. The TMEM-based signature gave us deep insight into immune cell infiltration profiles and provided an individualized immunotherapy strategy.
- | Journal, IO biomarker: Inducible co-stimulator inhibits lipid phagocytosis of human aortic smooth muscle cells by down-regulating CD36 expression. (Pubmed Central) - Mar 5, 2022
Similarly, the results of qPCR, western blot, and immunofluorescence staining showed that rICOS protein could down-regulate the ox-LDL-induced expression of CD36 in HASMCs, but this down-regulation was not as significant as that in JK-ICOS cells. ICOS could inhibit the lipid phagocytosis of HASMCs by down-regulating the expression of CD36, suggesting a potential anti-atherosclerosis (anti-AS) mechanism of ICOS, and preventing ox-LDL-induced formation of myogenic foam cells.
- | Journal, IO biomarker: Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production. (Pubmed Central) - Dec 22, 2021
While ICOS-ICOSL ligation is more likely to be engaged in cell adhesion, CD40-CD40L provides indispensable signal for B cell differentiation and IgG/IgM production. Our results are thus indicative for the segregating costimulation of CD40-CD40L and ICOS-ICOSL on CD4 T cells for B cell activation and differentiation, which might be helpful for the dissection of SLE pathogenesis.
- | Journal: Targeting ICOS expressed on CXCR5PD-1 T helper cells suppresses the progression of pemphigus vulgaris. (Pubmed Central) - Mar 16, 2021
Mouse DSG3-specific ICOS Tfh cells and human ICOSCXCR5PD-1 T helper cells are associated with the anti-DSG3 antibody response in PV. ICOS expressed on CXCR5PD-1 T helper cells may be a therapeutic target for PV.
- | Journal, IO biomarker: Exosome miR-27a-3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma. (Pubmed Central) - Mar 12, 2021
Adipocyte-derived exo-miR-27a-3p can inhibit ICOS T cell proliferation and IFN-gamma secretion. The upregulation of ICOS T cell functions caused by the downregulation of miR-27a-3p in adipose tissue derived exosomes is one of the potential mechanisms for the improved efficacy of immunotherapy in obese LUAD patients.
- | Journal, PD(L)-1 Biomarker, IO Biomarker: Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma. (Pubmed Central) - Dec 16, 2020
The upregulation of ICOS T cell functions caused by the downregulation of miR-27a-3p in adipose tissue derived exosomes is one of the potential mechanisms for the improved efficacy of immunotherapy in obese LUAD patients. Overall, these findings highlight Tfh and Tph-cells, IL-21 and the ICOS costimulatory pathway as key pathogenic players in SS immunopathology and exploitable therapeutic targets in SS.
- MEDI-570 / AstraZeneca, Japan Tobacco
[VIRTUAL] A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930) (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_924;
P1
A RP2D was established. MEDI-570 results in sustained reduction of the targeted ICOS+T lymphocytes.
- rozibafusp alfa (AMG 570) / AstraZeneca, Amgen
[VIRTUAL] SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF ROZIBAFUSP ALFA IN SUBJECTS WITH RHEUMATOID ARTHRITIS: INTERIM ANALYSIS OF A PHASE 1B RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE CLINICAL TRIAL (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_4269;
P1
PK/PD analysis demonstrated nonlinear, target-mediated disposition consistent with cell surface target interaction and PD activity consistent with dual ICOSL/BAFF neutralization. These findings informed the design and dose selection of an ongoing phase 2, randomized, placebo-controlled study to assess the efficacy and safety of rozibafusp alfa in subjects with active SLE and inadequate responses to standard of care therapy.
- Role of ICOS expressing CXCR5+PD-1+ T helper cells in pemphigus vulgaris (Board Number: P402) - Apr 25, 2020 - Abstract #IMMUNOLOGY2020IMMUNOLOGY_1121;
Furthermore, the administration of anti-ICOS blocking antibody to PV mice in vivo decreased the production of anti-DSG3 antibody and prevented disease activation. Therefore, ICOS+CXCR5+PD-1+ T helper cells are associated with the disease progression and can be a therapeutic target for PV.
- Endothelial inducible T cell co-stimulator ligand (ICOSL) regulates adhesion molecule expression on liver endothelium: implications for senescence-mediated immune surveillance (ePoster Area) - Jan 27, 2020 - Abstract #EASLHCC2020EASL_HCC_158;
We now demonstrate that levels of endothelial ICOSL regulates the function of conventional adhesion molecules, such as ICAM-1, in the specific recruitment of CD4+ T cells. This could be a unique pathway by which the SASP regulates the immune microenvironment of the liver.
- | Journal, IO Biomarker: ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy. (Pubmed Central) - Jul 11, 2019
ICOS/ICOS-L signal pathway has the potential to improve cancer treatment. However, studies in other models are needed to understand whether inhibition of ICOS expression or the blockage of its co-stimulation could be a potential therapeutic target or adjuvant treatment for immunotherapy.